People News

Share this article:

Hillis-Eden Pharmaceuticals, a manufacturer focused on small molecule compounds based on endogenous adrenal steroid hormones, announced the promotion of James Frincke to president and CEO. Frincke, previously chief scientific officer, was also elected to the company's board of directors. Hollis-Eden Pharmaceuticals is based in San Diego, CA.

 

Par Pharmaceuticals elected Thomas Rice to its board of directors. Rice was also appointed to the audit committee and nominating-corporate governance committee. Rice is a principal and co-founder of Columbia Investments, and was formerly CEO at Andrx Corporation while it was being sold to Watson Pharmaceuticals.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.